The Long View: Monitoring for Growth and Malignancy Risk
At a Glance
RAC2-related immunodeficiency does not mean cancer is inevitable. Persistent HPV or EBV may raise the chance of certain cancers in some patients, but evidence is limited, so specialists use individualized viral monitoring, exams, and targeted screening; biopsy may be needed for concerning findings.
Living with RAC2-related immunodeficiency involves more than managing day-to-day infections; it requires a long-term commitment to “watching and waiting.” Because the RAC2 protein supports leukocyte signaling and function, some people with RAC2 variants may have decreased ability to clear certain viruses. Over many years, these viruses can increase the risk of certain types of cancer, making routine surveillance a cornerstone of your long-term care plan [1][2]. It is important to note that persistent viral infection does not mean cancer is likely or already developing, and evidence is sparse and largely case-report based.
The Link Between Viruses and Cancer
- HPV (Human Papillomavirus): This virus is very common, but in people with RAC2 mutations, it can lead to severe or widespread warts that the body cannot clear [3]. If HPV stays active in the same area for many years, it can cause dysplasia (pre-cancerous changes) in tissues like the cervix, vagina, vulva, or anus. Case reports have documented gynecologic and anal neoplasms (tumors) in adults with specific RAC2 mutations who had long histories of viral disease [1].
- EBV (Epstein-Barr Virus): EBV is the virus that causes mononucleosis (“mono”). In most people, the virus becomes “dormant” after the initial illness. However, in immunodeficient patients, the virus can remain active or “reactivate.” Case reports have noted EBV-associated lymphoproliferation (such as Burkitt lymphoma in one kindred), but this does not establish a predictable cancer risk for all patients [4][2].
Recommended Surveillance and Screening
Because RAC2-related disease is so rare, there is no single “official” schedule that fits every patient. Instead, your doctors will create a risk-adapted plan based on your specific mutation and viral history [5].
HPV and Skin Monitoring
- Regular Skin Checks: You or your child’s doctor should inspect any persistent or treatment-resistant warts [6].
- Cytology: For patients with a history of persistent HPV or those reaching adolescence/adulthood, individualized cytology (such as cervical or anal screening depending on anatomy, age, and history) may be considered to look for early cellular changes [7].
- HPV Vaccination: The non-live HPV vaccine is generally used for prevention, though it does not treat existing infection and responses may be reduced in immunodeficiency. An individualized schedule should follow specialist guidelines [7].
EBV and Lymphoma Monitoring
- Quantitative PCR: This blood test measures the “viral load” or amount of EBV DNA in the blood. Detectable EBV DNA can occur without lymphoproliferative disease, and a rising level does not diagnose lymphoma in non-transplant patients [2].
- Physical Exams: Your doctor will regularly feel for lymphadenopathy (swollen lymph nodes) and splenomegaly (an enlarged spleen) [2].
- Imaging: If there is unexplained weight loss, night sweats, or persistent swelling, your doctor may order a CT scan or an FDG-PET/CT. Because PET scans cannot reliably distinguish reactive inflammation from malignancy, tissue biopsy with pathology is often the diagnostic standard when clinically indicated [8][9].
Navigating the Psychological Toll
The necessity of lifelong monitoring can lead to “scan anxiety”—the stress and worry that often precede medical tests and imaging. It is normal to feel a sense of dread or hyper-vigilance regarding every new lump or bump [10].
- Acknowledge the Burden: Recognize that “watching and waiting” is an active and exhausting part of your treatment. It is not “doing nothing”; it is a proactive strategy to catch issues early when they are most treatable.
- Seek Specialized Support: Genetic counselors and social workers who specialize in primary immunodeficiency (PID) can be invaluable. They can help you process the uncertainty of a rare diagnosis and provide tools for managing the anxiety that comes with long-term surveillance [11].
- Individualized Planning: Having a written surveillance calendar can help you feel more in control of the process. Knowing exactly when and why tests are happening can reduce the feeling of “waiting for the next shoe to drop” [12]. Please call your doctor right away rather than wait for a routine visit if you experience unexplained weight loss or rapidly enlarging nodes.
While the risk of malignancy is a serious aspect of RAC2-related disease, the goal of surveillance is to move from a place of fear to a place of informed action. By staying vigilant and working closely with a multidisciplinary team of immunologists, oncologists, and infectious disease specialists, you are taking the most powerful steps possible to protect your or your child’s long-term health [13].
Common questions in this guide
Does RAC2-related immunodeficiency mean that I or my child will develop cancer?
How is EBV monitored in RAC2-related immunodeficiency?
What HPV screening may be needed with RAC2-related immunodeficiency?
What symptoms should prompt a medical evaluation?
Can a PET/CT tell whether a swollen lymph node is lymphoma?
How can we cope with anxiety about lifelong monitoring?
One line in your results can change your plan.
A PET scan cannot reliably separate inflammation from malignancy, so a tissue biopsy is often the diagnostic standard when clinically indicated. We check your results against the latest research to help you prepare for what’s next.
Get notified when new evidence is published on RAC2-related combined immunodeficiency-bronchiectasis-cancer-predisposing syndrome.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (13)
- 1
Case Report: Characterization of a RAC2 R68W homozygous activating mutation causing combined immune deficiency.
Desjardins A, Marois L, Donkó Á, et al.
Frontiers in immunology 2026; (17()):1723142 doi:10.3389/fimmu.2026.1723142.
PMID: 41685306 - 2
Inborn Errors of Immunity in Pediatric Hematology and Oncology: Diagnostic Principles for Clinical Practice.
Roberti G, Maestrini G, Polito B, et al.
Journal of clinical medicine 2025; (14(17)) doi:10.3390/jcm14176295.
PMID: 40944054 - 3
A Novel RAC2 Mutation Causing Combined Immunodeficiency.
Zhang L, Lv G, Peng Y, et al.
Journal of clinical immunology 2023; (43(1)):229-240 doi:10.1007/s10875-022-01373-8.
PMID: 36190591 - 4
Phenotypic spectrum in a family with a novel RAC2 p.I21S dominant-activating mutation.
Ashby L, Chan L, Winterbourn C, et al.
Clinical & translational immunology 2024; (13(2)):e1493 doi:10.1002/cti2.1493.
PMID: 38410820 - 5
Epidemiology and management of malignancies in patients with inborn errors of immunity-An ESID registry study of 19,959 patients.
Bogaert DJA, Wolfsberger CH, Attarbaschi A, et al.
The Journal of allergy and clinical immunology 2026; (157(3)):739-753 doi:10.1016/j.jaci.2025.10.033.
PMID: 41242640 - 6
Targeting Complex Cutaneous Viral Infections in Search of Inborn Errors of Immunity.
Do Carmo AP, Battle AR, Fragnan NTML, et al.
Acta dermato-venereologica 2025; (105()):adv41318 doi:10.2340/actadv.v105.41318.
PMID: 40488587 - 7
Hyper-IgE and Carcinoma in CADINS Disease.
Pietzsch L, Körholz J, Boschann F, et al.
Frontiers in immunology 2022; (13()):878989 doi:10.3389/fimmu.2022.878989.
PMID: 35651609 - 8
Multidisciplinary Delphi consensus on malignancy screening in patients with common variable immunodeficiency.
Cabanero-Navalon MD, de Andrés-Martín A, Gil AA, et al.
Frontiers in immunology 2026; (17()):1897051 doi:10.3389/fimmu.2026.1897051.
PMID: 42676356 - 9
The Dark Side of Activated Phosphoinositide 3-Kinase-δ Syndrome 2: A Story Rewritten through FDG-PET.
Catelli A, Nanni C, Mulè R, et al.
Journal of clinical medicine 2024; (13(8)) doi:10.3390/jcm13082203.
PMID: 38673479 - 10
Global Expansion of Jeffrey's Insights: Jeffrey Modell Foundation's Genetic Sequencing Program for Primary Immunodeficiency.
Quinn J, Modell V, Johnson B, et al.
Frontiers in immunology 2022; (13()):906540 doi:10.3389/fimmu.2022.906540.
PMID: 35757720 - 11
Genetic Counseling in Pediatric Inborn Errors of Immunity: Perspective Piece on Current Practice and Considerations.
DeBortoli E, McInerney-Leo A, Macintosh R, et al.
The journal of allergy and clinical immunology. In practice 2025; (13(8)):1918-1927 doi:10.1016/j.jaip.2025.03.052.
PMID: 40252833 - 12
Customizing subcutaneous immunoglobulin administration in primary antibody deficiency: patient-centric care perspectives.
Kobayashi RH, Maltese J, Litzman J, et al.
Immunotherapy 2024; (16(20-22)):1235-1245 doi:10.1080/1750743X.2024.2436343.
PMID: 39648657 - 13
Inborn Errors of Immunity and Cancer.
Tiri A, Masetti R, Conti F, et al.
Biology 2021; (10(4)) doi:10.3390/biology10040313.
PMID: 33918597
This page is for informational purposes only and does not constitute medical advice. Your immunology team should tailor RAC2-related surveillance to your or your child's age, anatomy, genetic findings, and viral history.